“Uncovering the Truth: Levi and Korsinsky Investigate Universal Display Corporation”

Investigation of Universal Display Corporation Introduction On January 23, 2025, Levi & Korsinsky announced that they have initiated an investigation into Universal Display Corporation (NASDAQ:OLED) for potential violations of federal securities laws. This investigation comes following the company’s positive 2Q 2024 results and an upward revision of its full year revenue forecast on August 1,…

Read More

Title: ImmunityBio’s Q4 Loss Widens, Falls Short of Revenue Estimates: A Closer Look at IBRX’s Financial Performance

ImmunityBio (IBRX) Surprises with Narrower-than-Expected Q3 Loss ImmunityBio, Inc. (IBRX), a clinical-stage biotechnology company focusing on developing immune-oncology therapies, recently reported its third-quarter 2022 financial results. The company recorded a loss of $0.15 per share, which was narrower than the Zacks Consensus Estimate of a loss of $0.26. This improvement can be attributed to lower…

Read More

“Unlocking the Potential: XDC Network Leads the Way with $400 Million Token Release”

The Impact of Large Token Unlocks on Cryptocurrency Projects Introduction The week between February 3 and February 10 will see a significant unlock of tokens across various cryptocurrency projects, with a total value exceeding $400 million. According to data from Tokenomist, XDC Network (XDC) is expected to lead the cliff unlocks during this period, with…

Read More

“Calling All Millennials: How to Score an Extra $6,000 in 2025 (Without Selling Your Soul to Corporate America)”

How to Save Money: A Guide for Millennials The Financial State of Millennials Around 31% of Millennials currently have under $1,000 in savings. Another 21% have between $1,000-$5,000, and then 9% of Millennials have $5,001-$10,000. Does that seem bleak? Yes. Absolutely. The neutral news is that this percentage mirrors their Generation Z and Generation X…

Read More

CEO of Tevogen Bio Advocates for Long COVID Patients at Capitol Hill, Showcasing Positive Trial Results and Utilizing Company Assets for Combatting the Disease

Welcome to Tevogen Bio Holdings Inc. Reissuing Topline Results from Proof-of-Concept Clinical Trial Overview WARREN, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today reissues its previously announced…

Read More